Aoxing Pharmaceutical Company, Inc. announced earnings results for the second quarter and six month periods ended December 31, 2013. For the quarter, the company's revenues for the three ended December 31, 2013 were $3,466,807, representing a 5% increase over the revenues realized in the comparable periods of fiscal year 2013. The increase in revenue was mainly attributable to the increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Sales of Zhongtongan accounted for 90% of sales during the quarter ended December 31, 2013. The resulting net loss recorded for the three months ended December 31, 2013 was $1,917,469, whereas the company's net loss for the three months ended December 31, 2012 was $3,135,661.

For the six months, the company's revenues for the six months ended December 31, 2013 were $7,043,915, representing a 19% increase over the revenues realized in the comparable periods of fiscal year 2013. The increase in revenue was mainly attributable to the increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Sales of Zhongtongan accounted for 90% of sales during the quarter ended December 31, 2013. The net loss of $4,268,443 for the six months ended December 31, 2013 exceeded the net loss of $3,584,176 recorded in the comparable period of the prior year.